

# Quick Analysis of a Stock

Company/Ticker: **Regeneron Pharm/REGN**

Industry: **Bio-Tech/Healthcare**

Value Line Date/Page: **06/04/2021** Sales (\$): **\$8.5B**  
Completed)

In Year: **2020** (Recent Year

Size (Sales): VS (< \$1B);

**M (> \$1 - \$10B);**

L (> \$10B);

#	STANDARD	VALUE LINE DATA	SCORE
1	SALES GROWTH HISTORY: 1 point each for any of the past 10 yrs in which sales increased (max 10 points)	10/10	10
2	SALES GROWTH RATE: Doubling of sales in 5 years or less, 10 points; subtract 2 points for each additional year.	5	10
3	EPS GROWTH HISTORY: 1 point each for any of the past 10 years in which EPS increased (maximum 10 points)	7/10	7
4	EPS GROWTH RATE: Doubling of EPS in 5 years or less, 10 points; subtract 2 points for each additional year.	3	10
5	DIVIDEND GROWTH HISTORY: 1 point each for any of the past 5 years in which dividend increased (maximum 5 points)	N/A	0
6	3-YEAR OPERATING MARGIN (OM) RANGE: 10% OR Less: 5 points      11 – 14%: 8 points 15 - 19%: 12 points      20% or More: 15 points	35.4%	15
7	3-YEAR ON EQUITY (ROE) RANGE: 10% OR Less: 5 points      11 – 14%: 8 points 15 - 19%: 12 points      20% or More: 15 points	22%	15
8	LONG-TERM DEBT AS % OF SHR. EQUITY: 60% or more: 0 point;      30-60%: 3 points; less than 30%: 5 points	18%	5
9	CURRENT ASSETS-TO-CURRENT LIABILITY RATIO: Less than 1: 0 point; (1 – 2): 3 points; more than 2: 5 points	3.63	5
10	FUTURE EPS GROWTH PROJECTIONS: 10% OR Less: 5 points      11 – 14%: 8 points 15 - 19%: 12 points      20% or More: 15 points	12.5%	8
	TOTAL SCORE: 80 – 100: Superior; 60 – 79: Average; less than 60: Below Average	<b>Superior</b>	<b>85</b>